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Abstract
Background: Clostridium difficile infection (CDI) is the leading cause of infectious nosocomial diarrhoea but the
economic costs of CDI on healthcare systems in the US remain uncertain.
Methods: We conducted a systematic search for published studies investigating the direct medical cost associated
with CDI hospital management in the past 10 years (2005–2015) and included 42 studies to the final data analysis
to estimate the financial impact of CDI in the US. We also conducted a meta-analysis of all costs using Monte Carlo
simulation.
Results: The average cost for CDI case management and average CDI-attributable costs per case were $42,316
(90 % CI: $39,886, $44,765) and $21,448 (90 % CI: $21,152, $21,744) in 2015 US dollars. Hospital-onset CDI-
attributable cost per case was $34,157 (90 % CI: $33,134, $35,180), which was 1.5 times the cost of community-
onset CDI ($20,095 [90 % CI: $4991, $35,204]). The average and incremental length of stay (LOS) for CDI inpatient
treatment were 11.1 (90 % CI: 8.7–13.6) and 9.7 (90 % CI: 9.6–9.8) days respectively. Total annual CDI-attributable
cost in the US is estimated US$6.3 (Range: $1.9–$7.0) billion. Total annual CDI hospital management required nearly
2.4 million days of inpatient stay.
Conclusions: This review indicates that CDI places a significant financial burden on the US healthcare system. This
review adds strong evidence to aid policy-making on adequate resource allocation to CDI prevention and
treatment in the US. Future studies should focus on recurrent CDI, CDI in long-term care facilities and persons with
comorbidities and indirect cost from a societal perspective. Health-economic studies for CDI preventive intervention
are needed.
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Background
Clostridium difficile is the leading cause of infectious
nosocomial diarrhoea in the United States (US) [1] and
the incidence and severity of C. difficile infection (CDI)
are increasing [2]. CDI is associated with significant
morbidity and mortality; it represents a large clinical
burden due to the resultant diarrhoea and potentially
life-threatening complications, including pseudomem-
branous colitis, toxic megacolon, perforations of the
colon and sepsis [3–5]. Up to 25 % of patients suffer
from a recurrence of CDI within 30 days of the initial in-
fection. Patients at increased risk of CDI are those who
are immuno-compromised, such as those with human
immunodeficiency virus (HIV) or who are receiving
chemotherapy [6–8], patients receiving broad-spectrum
antibiotic therapy [9, 10] or gastric acid suppression
therapy [9, 11], patients aged over 65 years [10], patients
with serious underlying disease [12], patients in intensive
care units (ICUs) [10], or patients who have recently
undergone non-surgical gastrointestinal procedures or
those being tube-fed [10].
CDI represents a significant economic burden on US
healthcare systems. Infected patients have an increased
length of hospital stay compared to uninfected patients,
besides there are significant costs associated with treat-
ing recurrent infections. A few systematic reviews of
cost-of-illness studies on CDI cost are available [13–21].
These reviews mainly listed the range of reported cost of
their respective observation period or were limited by
the small number of included studies or inadequate con-
trol for confounding factors. No meta-analysis of large
number of cost data in the US has been conducted to
date. The cost for patients discharged to long-term care
facility (LTCF) and recurrent CDI management are
understudied. The cost of case management and total fi-
nancial burden of CDI treatment in the US is therefore
underestimated and remains controversial.
The aim of the current study is to conduct a system-
atic review and meta-analysis of currently available data
to identify and quantify the financial burden attributable
to CDI, and to further estimate the total economic bur-
den of CDI hospital management in the US.
Methods
Search strategy
English-language databases with online search tools were
searched for to offer maximum coverage of the relevant
literature: Medline (via the Ovid interface 1946 to July
2015); EMBASE (via the Ovid interface 1980 to July
2015); The Centre for Review and Dissemination Library
(incorporating the DARE, NHS EED, and NHS HTA da-
tabases); The Cochrane Library (via the Wiley Online Li-
brary) and Health Technology Assessment Database
(1989 to July 2015).
We supplemented our data by searching relevant pub-
lished reports from: National epidemiological agencies,
Google search for grey literature and hand searched the
reference lists of the included studies. The general
search headings identified were: Clostridium difficile,
economic, costs, cost analysis, health care costs, length
of stay, hospitalization. Examples of the strategy for
Medline and EMBASE are listed in Additional file 1.
Study selection
All studies that reported novel direct medical cost and/
or indirect costs related to CDI management were in-
cluded. Review articles, comments, editorials, letters,
studies of outbreaks, case reports, posters and articles
reporting results from economic modelling of a single
treatment measure (i.e. cost effectiveness of faecal trans-
plantation) were excluded in the final analysis. All rele-
vant publications from January 2005 to July 2015 were
included in the search. We included the following
healthcare settings: hospitals, long-term care facilities
and community. Geographical scope covered the US.
We did not apply any language restriction. Our prede-
fined inclusion and exclusion criteria are shown in Add-
itional file 1.
Data extraction
Two reviewers (SP, SZ) independently selected the in-
cluded articles and extracted data. After combining their
results, any discrepancies were solved by discussion with
HN and MK.
The primary outcomes were CDI-related costs (total
costs of those with CDI and other comorbidities) and
CDI-attributable costs (total costs of CDI management
only, after controlling for the confounders). For studies
with control groups (e.g. matched patients without CDI),
the CDI-attributable cost extracted was either the cost
provided by the articles or calculated by reviewers using
the CDI-related cost minus the treatment cost of control
groups. The secondary outcome was resource utilization
associated with CDI, i.e. CDI-related length of stay
(LOS) in hospital and CDI-attributable LOS. The study
characteristics of each article were extracted. These in-
cluded basic publication information, study design, stat-
istical methods, economic data reporting characteristics
and population information.
When multiple cost data were presented in a study,
we included only one cost estimate for each population
subgroup as per the priority below:
a. Matched data > Unmatched data.
b. Adjusted model results > Unadjusted model results.
c. Regression model results > Calculated difference.
d. Total cost/charges > Subgroup cost/charge (i.e.
survivors, died).
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e. Median (Interquantile Range: IQR) >Mean
(Standard Deviation, SD).
All costs/charges data were inflated to 2015 US$
equivalent prices adjusted for the Consumer Price Index.
If the price year was not reported, it was assumed to be
the last year of the data collection period. In cases where
charges were reported without cost-to-charge given,
costs were estimated using a cost-to-charge ratio of 0.60,
which is commonly used value in US health economic
studies [22].
Meta-analysis and estimation of national impact
We carried out meta-analysis for cost studies following a
Monte Carlo simulation approach, as reported by Jha et al
[23] and Zimlichman et al [17], bearing in mind the het-
erogeneity of the included studies. For each subgroup of
CDI, we synthesized the data and reported a point esti-
mate and 90 % confidence intervals (CIs) for the CDI-
related cost, CDI-attributable cost and their respective
LOS. For each included study, we simulated distribution
with pooled results weighted by sample size. We fitted a
triangular distribution for each of the included studies
based on their reported measures of central tendency and
dispersion, i.e. mean and 95 % CI, median and IQR, or
median and range. Then we simulated 100,000 sample
draws from the modeled distribution of each study. At
each iteration, we calculated the weighted average of all
included studies. Finally, we reported the mean and 90 %
CI from the resulting distribution of the 100,000 weighted
average of CDI. This approach facilitated the combination
of cost data and eliminated the limitation of combining
non-normally distributed data. Monte Carlo simulations
were conducted using the Monte Carlo simulation soft-
ware @RISK, version 7.0 (Palisade Corp).
We estimated the national financial impact of CDI on
the US healthcare system, by determining the potential
boundaries. The higher boundary was the total number
of CDI cases in the US in 2011 extracted from Lessa et
al [24], while the lower boundary was the result from a
meta-analysis to estimate the total burden of CDI cases
in the US [25] (For detailed results see Additional file 1).
The total annual cost of CDI management was calcu-
lated multiplying the average cost of management per
case of CDI, with the total number of CDI cases per year
in the US (Fig. 1). We assumed that all CDI cases
received treatment in hospital. A point estimate of the
final cost (with range) was reported based on a Monte
Carlo simulation of 100,000 sample draws.
Sensitivity analysis
We extracted the total number of CDI patients and
CDI-attributable costs from previous studies [25] and re-
views [17, 26] to carry out a sensitivity analysis of our
total cost estimates.
Quality assessment
The quality of the studies included was assessed mainly
based on the complexity of the statistical method (Fig. 2).
All studies were included in the final analyses.
Results
Search results
The search strategy identified 2671 references from data-
bases. Seven additional references were identified through
other sources. After screening the titles, abstracts and rele-
vant full texts (Fig. 3), a total of 42 studies were included in
this review.
Study characteristics
The characteristics of the 42 included studies [27–68] are
summarized in Table 1. Cost data collection periods
ranged from 1997 to 2012. Most studies (n = 27) used na-
tional level databases, with 17 used National Independent
Sample (NIS) database and the remaining 10 studies ex-
tracted data from various national databases. Fifteen stud-
ies were conducted at state level, of which 6 studies only
collected data in single hospital. All studies reported cost
in hospital level of care, no articles identified in LTCF and
community. Nearly all identified references were retro-
spective hospital database studies (n = 40) and only 1
study was a prospective observational study [29] and an-
other study was a decision tree model [48].
Most studies (n = 15) investigated economic outcomes
in all age inpatients. Three studies reported cost data in
children less than 20 years old. The mean/median age of
the CDI patient groups ranged from 47.4 to 73.0 years.
Other studies investigated complicated CDI in high-risk
patient groups, such as those with major surgery (n =
16), inflammatory bowel diseases (n = 2), liver or renal
disease (n = 4), elderly (n = 2) and ICU patients (n = 1).
There was 1 study each in non-surgical inpatients, sepsis
Fig. 1 Formula for total annual cost calculation
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Fig. 2 Quality Assessment Method
Fig. 3 PRISMA diagram of economic burden search of C. difficile
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Table 1 Overview of selected references that assessed economic burden attributable to CDI by type of CDI considered in the US
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Table 1 Overview of selected references that assessed economic burden attributable to CDI by type of CDI considered in the US (Continued)
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± 19.4;








16 Lagu 2014 [42] Massachusetts,
Boston one
hospital










17 Lameire 2015 National 2002–2009 Comp. Cardiac
surgery
512,217 421,294 >40
CABG 65.4 ± 10.5








Missouri 1997–1999 Both ICU 1872 76 Primary 68.9 (34–93)
Secondary 58.7 (16–91)
Toxin assay Medium No matching;
regression
A 19-bed medical ICU in a


















- The SPARCS database-
acute care non-federal hospi-
tals in New York State
21 Maltenfort 2013
[47]




















24 Nylund 2011 [50] National 1997,2000,
2003,2006

























OT-CDI 58 ± 16 a;






28 Pant 2012 (2)
[54]
National 2009 Both Renal
disease
184,139 5151 >18,
ESRD + CDI 66 ± 14




























Table 1 Overview of selected references that assessed economic burden attributable to CDI by type of CDI considered in the US (Continued)
Inpatient Database (HCUP-
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Toxin assay High Matching;
regression
The Johns Hopkins hospital
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Six Pennsylvania hospitals via
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Abbreviations: NR not reported, IBD inflammatory bowel disease, LOS length of stay, ICU intensive care unit, retrosp. retrospective, Comp. complicating, Req. requiring, both requiring and complicating, PD primary














inpatients and patients with prolonged acute mechanical
ventilation. There was 1 study focusing only on recur-
rent CDI in the general population.
The sample sizes of included studies ranged from 85
to 7,227,788, with a median sample size of 83,939. A
total of 28.8 million inpatient hospital-days were ana-
lysed, of which 1.31 million inpatient hospital-days were
CDI patients. The median sample size of CDI population
was 2938.
The methods to identify CDI varied according to the
type of CDI that was assessed in the study. CDI cases
were identified either with laboratory test, i.e. positive C.
diffcile toxin assay, or hospital discharge diagnosis of C.
difficile (primary and/secondary) from administrative
datasets using the International Classifications of dis-
eases, Ninth, Clinical Modification, ICD-9-CM 008.45.
Clinical diagnosis was also used in two studies.
CDI was classified in three types: Community-onset
CDI (CO-CDI) requiring hospitalization, Hospital-onset
CDI (HO-CDI) complicating other diseases, or both CDI
(Table 2). Most of included studies considered HO-CDI
(n = 23) or both CDI types (n = 17). Only four studies in-
vestigated CO-CDI only. However, subgroup data of
CO-CDI is also available in studies that reported both
CDI types.
CDI costs and LOS
The mean CDI-attributable costs per case of CO-CDI
were $20,085 (Range: $7513–$29,662), lower than HO-
CDI $34,149 (Range:$1522–$122,318). HO-CDI showed
a wider range within which the additional cost for CDI
in the general population ranged from $6893 to $90,202
and in high risk groups ranged from $7332 in congestive
heart failure patients to $122,318 in renal impairment
patients. The mean CDI-attributable LOS was 5.7 days
(Range: 2.1–33.4) for CO-CDI, 7.8 (Range:2.3–21.6) days
for HO-CDI, and 13.6 (Range: 2.2–16) days for both
groups. Cost data and LOS for individual studies are
presented in Tables 3 and 4.
Using a Monte Carlo simulation, we generated point esti-
mates and 90 % CI for both cost and LOS; the meta-
analysis results are shown in Table 5. The total cost of in-
patient management of CDI-related disease was $42,316
(90 % CI: $39,886–$44,765) per case, of which the total
CDI-attributable cost was $21,448 (90 % CI: 21,152–
21,744) per case. For the inpatient management, the attrib-
utable cost for those HO-CDI was $34,157 (90 % CI:
$33,134–$35,180), which was 1.5 times as much as CO-
CDI management $20,095 (90 % CI: $4991–$35,204).
Similar patterns were observed in LOS data. The total
CDI-related LOS was 11.1 days (90 % CI: 8.7–13.6) and
CDI-attributable LOS was 9.7 (90 % CI: 9.6–9.8). The
HO-CDI patients had longer CDI-attributable LOS
9.7 days (90 % CI: 9.7–9.7) than CO-CDI patients
5.7 days (90 % CI: 4.1–7.3).
CDI annual national impact estimate
The total burden of healthcare facility CDI in US was es-
timated 293,300 (Range: 264,200–453,000) cases per year
[25]. The total financial burden of CDI inpatient man-
agement was estimated to be US$6.3 (Range: $1.9–$7.0)
billion in 2015, which required 2.4 million days of hos-
pital stay. The total CDI related disease management
cost was nearly doubled at US$12.4 (Range: $3.7–$14.4)
billion in 2015 (Table 6). A sensitivity analysis showed
that the total CDI-attributable cost ranged from $1.31 to
$13.61, which covers our estimates (Additional file 1).
Quality assessment
A summary of the quality assessment for statistical
methods in included studies is shown in Additional file
1. There were 13 studies of high quality, 21 studies with
medium quality and 8 low quality studies.
Discussion
We systematically reviewed 42 published cost studies of
CDI case management in the past 10 years (2005–2015)
and found a significant financial burden associated with
CDI in the US. The total CDI-attributable cost was
US$6.3 billion, which is higher than previously reported
(range US$1.1–4.8 billion) [14, 16, 17]. The mean cost
for CDI-attributable hospitalized patients per case was
US$21,448, nearly half of the mean CDI-related inpatient
cost.
This review facilitated a meta-analysis of a large num-
ber of cost studies for costs related to CDI management
and provided an uncertainty range. Zimlichman et al
[17] applied this method to calculate CDI cost based on
cost data from two cost-of-illness studies (O’Brian 2007
[51] & Kyne 2002 [69]) and obtained a lower cost
[2012US $11,285 ($9118–$13,574)] than ours. Our re-
view combined 100-point estimates and ranges from 42
individual studies, which provided more accurate and




CO-CDI - Discharge code ICD-9-CM 008.45 as Primary diagnosis
HO-CDI - Discharge code ICD-9-CM 008.45 as secondary diagnosis,
without a primary diagnosis of a CDI-related symptom
(e.g. diarrhea)
- Study population ≥ 48 h of hospitalization
- Symptom onset and/or positive laboratory assay at
least ≥ 48 h hospitalization
Both CDI - No distinction of settings of acquisition
- Discharge code ICD-9-CM 008.45 in any position
Abbreviations: CO-CDI community-onset CDI, HO-CDI hospital-onset CDI, ICD-9-
CM The International Classification of Diseases, Ninth Revision,
Clinical Modification
Zhang et al. BMC Infectious Diseases  (2016) 16:447 Page 8 of 18
Table 3 CDI-attributable costs/charges and CDI-related management costs/charges









SD, 95 % CI or
IQR
CO-CDI Inpatient Cost
Arora 2011 [29] General Cost Median 85 25,436 85 25,436
O’Brien 2007 [51] General Cost Mean 4015 14,736 4015 14,736
Peery 2012 [56] General Cost Median 110,553 7513 110,553 7513
VeerLee 2012 [64] General Charges Mean 68,686 74,211 120,156 68,686 74,211 120,156
Kuntz 2012 [41] General Cost Mean 1650 929 4800 1650 929 4800 Outpatient
Kuntz 2012 [41] General Cost Mean 1316 11,877 35,923 1316 11,877 35,923 Inpatient
O’Brien 2007 [51] General Cost Median 1036 7263 1036 7263 PD
VeerLee 2012 [64] General Charges Mean 17,413 27,463 40,484 17,413 27,463 40,484 PD
O’Brien 2007 [51] General Cost Mean 3327 16,946 34,655 3327 16,946 Rehospitalisation
Sammons 2013
[59]
Children Cost Mean 2060 19,993 15,973 24,013 2060 19,993 15,973 24,013 Community onset
Ananthakrishnan
2008 [28]
IBD Charges Median 44,400 16,864 CDI only
Pant 2013 [55] IBD Charges Mean 12,610 12,761 6868 18,655 447 50,050 CDI only
Bajaj 2010 [30] Cirrhosis Charges Mean 58,220 70,309 CDI only
Quimbo 2013 [57] CDI History Cost Mean 1866 29,662 20,798 42,300 933 51,863 36,641 73,411 CDI only
Total numbers/Weighted Mean 224,617 20,085 314,141 23,322
HO-CDI Inpatient Cost
Fuller 2009 [37] General Cost Coefficient 1282 18,466 288 1282 18,466 288 Maryland, SD
Fuller 2009 [37] General Cost Coefficient 2478 29,980 271 2478 29,980 271 California, SD
Lipp 2012 [46] General Cost Mean 3826 32,050 3826 32,050 SD
McGlone 2012
[48]




General Cost Median 54,046 11,116 9476 13,366 54,046 11,116 9476 13,366 10 days LOS
McGlone 2012
[48]
General Cost Median 54,046 12,194 10,146 14,896 54,046 12,194 10,146 14,896 14 days LOS
O’Brien 2007 [51] General Cost Median 2656 6630 2656 6630 SD
VeerLee 2012 [64] General Charges Mean 51,273 90,202 146,767 51,273 90,202 146,767 SD
Jiang 2013 [39] General Cost Median 7264 11,689 1211 21,751













Table 3 CDI-attributable costs/charges and CDI-related management costs/charges (Continued)
Pakyz 2011 [52] General Cost Median 30,071 24,456 10,857 39,598 22,400 88,537 Unadjusted
Pakyz 2011 [52] General Cost Mean 30,071 31,169 10,857 64,000 63,541 64,458 Adjusted
Tabak 2013 [63] General Cost Mean 1020 6893 1365 13,617 255 22,992 12,222 42,470
Campbell 2013
[31]
Age > = 65 Cost Mean 3064 7536 4302 10,771 3064 48,932 67,727
Quimbo 2013 [57] Elderly Cost Mean 34,732 45,749 43,279 48,359 10,933 83,004 78,548 87,713
Sammons 2013
[59]
Children Cost Mean 2414 99,012 84,626 113,398 2414 99,012 84,626 113,398
Ananthakrishnan
2008 [28]
IBD Charges Median 80,170 7655 2804 24,623
Ananthakrishnan
2008 [28]
IBD Charges Mean 80,170 14,368 9467 19,270 –
Campbell 2013
[31]
IBD Cost Mean 84 1522 −14,932 11,888 84 40,194 44,845
Quimbo 2013 [57] IBD cost Mean 3618 11,825 9851 14,181 1206 42,035 35,918 49,191
Ananthakrishnan
2008 [28]
Ulcerative colitis (UC) Charges Median 1843 26,750
Nguyen 2008 [49] UC Charges Mean 43,645 14,749 196 43,381 Regression
Ananthakrishnan
2008 [28]
Crohn's disease (CD) Charges Median 961 22,738
Nguyen 2008 [49] CD Charges Mean 73,197 14,316 329 41,453 Regression
Reed 2008 Digestive disorders Charges Mean 2394 3670 320 9076 8068
Damle 2014 [14] Colorectal surgery Cost Median 84,648 14,644 13,700 15,589 1266 21,309 38,218 –
Kim 2012 [40] Cystectomy Cost Mean 10,856 25,014 153 57,379 50,204 64,554
Lesperance 2011
[45]
Elective colonic resection Charges Mean 695,010 84,899 10,077 158,401
Reed 2008 Major bowel procedures Charges Mean 1035 25,476 45 47,064 31,302
Wilson 2013 [66] Ileostomy Cost Mean 13,462 20,272 217 35,076
Wilson 2013 [66] Ileostomy Cost Coefficient 13,462 17,513 14,106 20,921
Egorova 2015 [35] Vascular surgery Cost Median 450,251 14,250 4708 36,847 22,912 62,903
Flagg 2014 [36] Cardiac surgery Cost Median 5160 19,524 2580 213,661 Adjusted
Flagg 2014 [36] Cardiac surgery Cost Median 349,122 38,320 2580 72,730 Unadjusted
Lemaire 2015 [43] Cardiac surgery Cost Median 421,294 35,968 – 72,685 CABG
Lemaire 2015 [43] Cardiac surgery Cost Median 90,923 59,696 – 106,141 VS
Reed 2008 OR procedure for infectious
/parasitic diseases













Table 3 CDI-attributable costs/charges and CDI-related management costs/charges (Continued)
Glance 2011 [38] Trauma Cost Median 149,656 24,131 768 39,296
Campbell 2013
[31]
Cabx Cost Mean 1641 18,567 10,448 26,687 1641 78,948 99,739
Quimbo 2013 [57] Cabx Cost Mean 17,716 38,413 35,195 41,922 4429 64,242 59,145 69,780
Lagu 2014 [42] Sepsis Cost Median 4736 5792 4933 6665 2368 28,576 16,496 50,494
Reed 2008 Septicaemia Charges Mean 1211 9141 92 22,378 20,591
Campbell 2013
[31]
Renal impairment Cost Mean 3236 5024 1118 8928 3236 50,586 72,180
Quimbo 2013 [57] RI Cost Mean 22,132 122,318 111,315 134,405 5533 201,212 183,706 220,386
Ali 2012 [27] Liver transplant Charges Mean 193,714 77,361 5159 158,038
Singal 2014 [60] Cirrhosis Charges Mean 89,673 23,310 1444 47,401
Reed 2008 Congestive Heart Failure Charges Mean 2542 7332 35 14,738 13,841
Quimbo 2013 [57] Immunocompromised Cost Mean 14,344 33,632 30,151 37,516 3586 73,612 66,048 82,041
Campbell 2013
[31]
Cancer/BMT Cost Mean 782 687 −6480 7855 782 48,280 72,605
Total numbers/Weighted mean 3,020,827 34,149 207,801 49,712
Dubberke 2014 [2,
34, 71]
Recurrent CDI Cost Mean 3958 12,163 3958 11,523 4728 26,167 Total cost difference
Dubberke 2014 [2,
34, 71]
Recurrent CDI Cost Mean 3958 12,692 9752 15,919 Adjusted
Song 2008 [61] General Cost Median 1260 373 630 30,305
Stewart 2011 [62] General Cost Mean 82,414 9670 41,207 26,790
Wang 2011 [65] General Cost Median 7,227,788 4914 78,273 12,081
Nylund 2011 [50] Children Charges Median 3565 15,937 3565 25,549 1997
Nylund 2011 [50] Children Charges Median 4356 20,750 4356 31,858 2000
Nylund 2011 [50] Children Charges Median 5574 23,627 5574 33,625 11,348 97,822 2003
Nylund 2011 [50] Children Charges Median 7779 23,362 7779 35,444 13,601 110,343 2006
Sammons 2013
[59]
Children Cost Mean 698,616 51,304 44,746 57,969 698,616 51,304 44,746 57,969
Dubberke 2008
[33]
Non-surgical Cost Median 24,691 11,749 439 20,569 Raw data
Dubberke 2008
[33]
Non-surgical Charges Median 24,691 23,961 439 42,154 Raw data
Dubberke 2008
[33]
Non-surgical Cost Mean 24,691 3173 3078 3815 Linear regression


















Non-surgical Cost Mean 24,691 6520 4910 8381 Linear regression, 180 days
Dubberke 2008
[33]
Non-surgical Cost Median 24,691 9284 342 35,414 Matched cases, 180 days
Zerey 2007 [67] Surgical Charges Median 1,553,597 59,424 8113 81,708






Cost Median 64,910 48,065 3468 190,188 107,689 333,290 Unadjusted
Zilberberg 2009
[68]
PAMV Cost Mean 3370 12,616 9186 16,046 3468 91,039 71,306 Adjusted
Lawrence 2007
[44]
ICU Cost Median 1872 7043 76 15,016 ICU stay
Lawrence 2007
[44]
ICU Cost Median 1872 36,095 76 60,723 Entire hospital stay
Bajaj 2010 [30] Cirrhosis Charges Mean 83,230 49,460 1165 96,678
Maltenfort 2013
[47]
Arthroplasty Charges Median – 43,648 – 84,877 52,498 142,827
Pant 2012 [53] Organ transplant Charges Mean 49,198 77,246 73,412 81,080 63,651 42,054 69,033
Pant 2012 (2) [54] Renal disease Charges Coefficient 184,139 69,679 68,338 71,020 59,793 87,982
Pant 2013 [55] IBD Charges Mean 12,610 39,453 32,470 46,436
Total numbers/Weighted Mean 10,012,927 14,403 981,005 45,421
Abbreviations: CO-CDI community-onset CDI, HO-CDI hospital-onset, PAMV prolonged acute mechanical ventilation, Cabx concomitant antibiotic use, UC ulcerative colitis, CD Crohn’s disease, IBD inflammatory bowel
disease, ICU intensive care unit, CABG coronary artery bypass grafting, VS valvular surgery, BMT, PD primary diagnosis, SD secondary diagnosis, Calculated numbers were marked in Italic, attributable cost = cost of CDI













Table 4 CDI-attributable LOS and CDI-related LOS







Value SD or 95 %
CI
CO-CDI Inpatient days
Arora 2011 [29] Horn’s index 1&2 Mean 33 15.1 16.2 33 15.1 16.2
Arora 2011 [29] Horn’s index 3&4 Mean 52 33.4 33.3 52 33.4 33.3
Kuntz 2012 [41] General outpatient Mean 1650 10.0 17.0 1650 10.0 17.0
Kuntz 2012 [41] General inpatient Mean 1316 14.9 20.9 1316 14.9 20.9
O’Brien 2007 [51] General Mean 4015 6.4 4015 6.4
Pant 2013 [55] IBD Coefficient 12,610 2.1 1.4 2.8 2.1 1.4 2.8
Peery 2012 [56] General Median 110,553 5.0 110,553 5.0
Quimbo 2013 [57] CDAD History Mean 1866 2.9 2.4 3.6 933 8.9 7.2 11.0
Sammons 2013 [59] Children Median 2060 5.6 4.5 6.6 2060 6.0 4.0a 13.0a
VeerLee 2012 [64] General Mean 68,686 7.1 7.0 68,686 7.1 7.0
Weighted Mean 202,841 5.7 189,298 5.9
HO-CDI inpatient days
Jiang 2013 [39] General Median 7264 8.0 1211 13.0
Lipp 2012 [46] General Mean 3826 12.0 3826 12.0
Pakyz 2011 [52] General Mean 30,071 11.1 10,857 21.1 21.0 21.2
Tabak 2013 [63] General Median 1020 2.3 0.9 3.8 255 12.0 9.0a 21.0a
Wang 2013 General Median 7,227,788 7.0 78,273 6.0 4.0a 11.0a
Campbell 2013 [31] Age > = 65 Mean 3064 3.0 1.4 4.6 3064 21.3 25.3
Quimbo 2013 [57] Elderly Mean 34,732 7.8 7.5 8.1 10,933 18.8 18.2 19.5
Sammons 2013 [59] Children Median 2414 21.6 19.3 23.9 2414 23.0 12.0a 44.0a
Ananthakrishnan 2008
[28]
IBD Median 80,170 3.0 2804 7.0
Campbell 2013 [31] IBD Mean 84 3.0 −2.3 8.3 84 21.0 19.1
Quimbo 2013 [57] IBD Mean 3618 3.3 2.9 3.7 1206 12.8 11.6 14.2
Nguyen 2008 [49] Crohn’s disease Mean 73,197 3.8 329 9.5
Nguyen 2008 [49] Ulcerative colitis Mean 43,645 3.2 196 9.9
Reed 2008 Digestive disorders Mean 2394 3.0 320 6.9 5.2
Damle 2014 [14] Colorectal surgery Median 84,648 8.4 8.0 8.9 1266 13.0 18.0
Lesperance 2011 [45] Elective colonic resection Mean 695,010 11.7 10,077 22.6
Reed 2008 Major bowel procedures Mean 1035 10.0 45 20.9 11.3
Wilson 2013 [66] Ileostomy Mean 13,462 11.6 217 18.7
Campbell 2013 [31] Cabx exposure Mean 1641 7.8 5.7 9.9 1641 29.3 34.7
Quimbo 2013 [57] Concomitant Antibiotic Use Mean 17,716 7.8 7.4 8.3 4429 17.9 17.0 18.9
Lagu 2014 [42] Sepsis Mean 4736 5.1 4.4 5.7 2368 19.2
Reed 2008 Septicemia Mean 1211 5.0 92 10.7 7.6
Egorova 2015 [35] Vascular surgery Median 450,251 6.7 4708 15.0 9.0a 25.0a
Flagg 2014 [36] Cardiac surgery Median 349,122 10.0 2580 21.0
Glance 2011 [38] Trauma Median 149,656 10.0 768 16.0
Lemaire 2015 [43] Cardiac surgery (CABG) Median 421,294 12.0 19.0
Lemaire 2015 [43] Cardiac surgery (VS) Median 90,923 16.0 24.0
Reed 2008 Congestive Heart Failure Mean 2542 5.0 35 9.7 7.0
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comprehensive data of the cost result. Despite the meth-
odological heterogeneity in perspectives, treatment pro-
cedure and statistical analysis, each included study met
our inclusion criteria, which were defined to identify
studies that provided real world estimates of costs,
therefore the combination of these data with uncertainty
range represented a valuable and reliable summary of
CDI-related cost.
Furthermore, we evaluated hospital onset CDI and com-
munity onset CDI separately. We found that CDI compli-
cating hospitalization cost more than CDI requiring
hospitalization and the former had longer attributable
hospital stay. Therefore, other factors, such as comorbid-
ity, may contribute to infections and increase the difficulty
of CDI treatment.
We estimated that the total cost attributable to CDI
management in the US was nearly US$6.3 (Range:
$1.9–$7.0) billion, which is similar to Dubberke and
Olsen’s estimates at $4.8 billion [14], but significantly
higher than other studies (US$ 1.5 billion in Zimlichman
et al [17] and $1.1 billion in Ghantoji et al [16]). The
later studies reported lower attributable cost per case
based on a limited number of studies before 2005, which
arguably is out-of-date. To compare with the latest
Table 4 CDI-attributable LOS and CDI-related LOS (Continued)
Reed 2008 OR procedure for infectious /parasitic
diseases
Mean 449 2.0 32 14.7 8.6
Lawrence 2007 [44] ICU Median 76 14.9 1.0b 86.0b
Lawrence 2007 [44] ICU Median 76 38.3 4.0b 184.0b
Ali 2012 [27] Liver transplant Mean 193,714 10.1 5159 17.8
Singal 2014 [60] Cirrhosis Mean 89,673 7.5 1444 13.9
Quimbo 2013 [57] Immunocompromised Mean 14,344 8.4 7.9 9.0 3586 22.1 20.6 23.7
Campbell 2013 [31] Renal impairment Mean 3236 4.0 2.9 5.1 3236 22.7 28.2
Quimbo 2013 [57] Renal impairment Mean 22,132 17.3 16.4 18.3 5533 37.5 35.5 39.6
Campbell 2013 [31] Cancer/BMT Mean 782 4.0 2.3 5.7 782 21.3 18.5
Weighted Mean 10,120,864 7.8 168,892 13.5
Both CO-CDI and HO-CDI inpatient cost
Song 2008 [61] General Median 1260 4.0 630 22.0
Stewart 2011 [62] General Mean 82,414 5.1 41,207 13.0 14.0
Nylund 2011 [50] Children, 1997 Median 3565 3.0 3565 5.0 3.0a 14.0a
Nylund 2011 [50] Children, 2000 Median 4356 4.0 4356 6.0 3.0a 15.0a
Nylund 2011 [50] Children, 2003 Median 5574 4.0 5574 6.0 3.0a 14.0a
Nylund 2011 [50] Children, 2006 Median 7779 4.0 7779 6.0 3.0a 15.0a
Sammons 2013 [59] Children Median 698,616 12.2 10.6 13.8 698,616 10.0 5.0a 23.0a
Bajaj 2010 [30] Cirrhosis Mean 83,230 7.1 1165 14.4
Bajaj 2010 [30] CDI only Mean 58,220 12.7
Pant 2013 [55] IBD Mean 12,610 2.2 1.5 2.8 447 8.2
Dubberke 2008 [33] Non-surgical Median 24,691 6.0 439 10.0 2. 0b 87.0b
Lawrence 2007 [44] ICU stay Median 1872 3.1 76 6.1 1.0b 86.0b
Lawrence 2007 [44] Hospital stay Median 1872 14.4 76 24.5 2.0b 184.0b
Maltenfort 2013 [47] Arthroplasty Median – 7.0 – 10.0 7.0a 17.0a
Zerey 2007 [67] Surgical Median 1,553,597 16.0 15.6 16.4 8113 18.0
Pant 2012 [53] Organ transplant Median 49,198 9.6 9.3 9.9 63,651
Pant 2012 (2) [54] Renal disease Coefficient 184,139 9.4 9.2 9.5 59,793
Zilberberg 2009 [68] Prolonged acute mechanical ventilation Median 3370 6.1 4.9 7.4 3468 25.0 15.0a 40.0a
Weighted Mean 2,718,143 13.6 957,175 9.0
Abbreviations: CO-CDI community-onset CDI, HO-CDI Hospital-onset CDI, PAMV prolonged acute mechanical ventilation, Cabx concomitant antibiotic use, UC ulcera-
tive colitis, CD Crohn’s disease, IBD inflammatory bowel disease, ICU intensive care unit, CABG coronary artery bypass grafting, VS valvular surgery, BMT, PD primary
diagnosis, SD secondary diagnosis, Calculated numbers were marked in Italic, attributable cost = cost of CDI group- cost of control non-CDI group
aQ1-Q3
bMin-Max
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review on global CDI cost (Nanwa et al [26]), this review
identified 8 additional studies with recent data. Nanwa
et al [26] found that the mean attributable CDI costs
ranged from US$8911 to US$30,049, which is similar to
our results.
In this study, we only assessed the quality of study em-
phasizing statistical methods and did not use the modified
economic evaluation guideline as other COI systematic re-
views. Cost and LOS estimation of healthcare-associated
infections has the potential to be misleading if the con-
founders such as patients’ comorbidities or daily severity
of illness were not properly controlled for. Using either
the matching design or multivariable regression analysis
allows to control known confounders and may, in part,
address selection bias [70]. We found that whether ad-
vanced statistical methods were used and described was
crucial for the assessment of data quality, which has not
be fully captured by the existing quality assessment tool.
Therefore in this study we assessed quality of included
studies using this new method. Moreover, Nanwa et al
[26] has evaluated the methodological completeness of
most included studies (34 out of 42); we agree with their
recommendations regarding possible improvement of fu-
ture cost-of-illness study. However, we need to bear in
mind that cost effects or excess LOS are still likely to be
overestimated if the interval to onset of HAI is not prop-
erly accounted for in the study design or analysis [70].
Our systematic review has some limitations. First, all in-
cluded studies reported direct medical costs from hospital
perspective, therefore indirect cost to patients and society
and costs of additional care after hospital discharge, have
not been captured. No studies reported indirect cost
(productivity loss due to work day losses) of patients or
care-givers, and we failed to identify studies assessing cost
of CDI in long-term care facilities, where about 9 % of
CDI patients were discharged to for an average of 24 days
of after-care. This would result in an additional US$141
million burden on the healthcare system and society due
to LTCF transfers [14]. Second, we did not separate pri-
mary CDI from recurrent CDI cost in our review because
only two studies reported cost specifically to recurrent
CDI $12,592 (Range: $9752, $15,919) [2]. Moreover, we
found it difficult to exactly match the CDI case definition
in cost study (e.g. ICD10 Code primary diagnosis and sec-
ondary diagnosis) with the case definition in epidemiology
studies (e.g. community onset, hospital onset), therefore
we did not estimate CDI patients managed at outpatient
and community settings due to lack of both epidemiology
and economic data. The total costs of CDI management
may be higher than our current estimate. Fourth, unlike
other published reviews, we did not include cost studies
from countries other than the US nor facilitate any inter-
national comparison. This study initially aimed to identify
cost-of-illness studies in North America, but we did not
find any studies reporting cost data from Canada. This is
likely because we restricted our search to English language
databases. Therefore the cost of CDI management in
Canada remains unknown. However, we did not apply any
language restrictions to the current review.
Effective prevention can reduce the burden of diseases.
Strategies have been promoted such as appropriate use
Table 5 Meta analysis results of cost and LOS of CDI management
CDI category CDI-attributable cost per case
(2015 US$)
CDI-related cost per case
(2015 US$)
CDI-attributable LOS per case
(Days)
CDI-related LOS per case
(Days)
Weighted mean 90 % CI Weighted mean 90 %CI Weighted mean 90 % CI Weighted mean 90 % CI
CO-CDI 20,095 4991 35,204 23,329 12,520 34,141 5.7 4.1 7.3 5.7 4.1 7.3
HO-CDI 34,157 33,134 35,180 53,487 42,054 66,326 9.7 9.7 9.7 14.1 13.0 15.4
Both CO-CDI
and HO-CDI
17,650 17,292 18,009 46,000 42,502 49,533 10.4 9.7 11.0 11.8 7.1 17.6
Overall inpatient 21,448 21,152 21,744 42,316 39,886 44,765 9.7 9.6 9.8 11.1 8.7 13.6
Abbreviations: CO-CDI community-onset CDI, HO-CDI Hospital-onset CDI
Table 6 Total cost of CDI management in US
Total number of HCF CDI cases per
year (2011) [25]
Mean 95 % CI
All population ≥2 years Median 293,300 264,200 322,500
Adults ≥18 Upper boundary 288,900 261,100 316,700
Adults ≥18 Lower boundary 133,887 91,780 195,402





Overall CDI-attributable cost 21,448 21,152 21,744
Overall CDI-related cost 42,316 39,886 44,765
Total cost per year







Mean 6.29 5.59 7.01
Upper boundary 6.19 5.52 6.88
Lower boundary 2.87 1.94 4.25
Total CDI-related cost per year 12.41 3.66 14.44
Mean 12.41 5.59 14.44
Upper boundary 12.25 10.41 14.18
Lower boundary 5.67 3.66 8.75
Abbreviations: HCF healthcare facility, CDI clostridium difficile infection, CI
confidence intervals
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of antimicrobials, use of contact precautions and pro-
tective personal equipment to care for infected patients,
effective cleaning and disinfection of equipment and the
environment, and early recognition of disease as primary
prophylaxis [71]. As CDI is an infectious disease, the
population at risk would benefit from an effective vac-
cine, which is currently under development [72, 73].
More cost of illness studies for recurrent CDI, or in
LTCF, and indirect cost from a societal perspective are
needed in the future. We would also recommend that
published studies report their methods and include point
estimates with uncertainty range. Further economic
studies for CDI preventive interventions are needed.
Conclusion
This review indicates that CDI places a significant finan-
cial burden on the US healthcare system. In addition,
our findings suggest that the economic burden of CDI is
greater than previously reported in the US. This review
provides strong evidence to aid policy-making on ad-
equate resource allocation to CDI prevention and treat-
ment in US.
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